SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

HLS Therapeutics Inc. HLTRF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

HLS Therapeutics Inc. (HLTRF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $3.21. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $56M, -2.6%/yr average growth. Net income is $13M (loss), growing at +15.9%/yr. Net profit margin is -22.4% (negative). Gross margin is 42.5% (-49.4 pp trend).

Balance sheet: total debt is $50M against $62M equity (Debt-to-Equity (D/E) ratio 0.81, moderate). Current ratio is 1.11 (adequate). Debt-to-assets is 36.2%. Total assets: $137M.

Analyst outlook: 0 / 1 analysts rate HLTRF as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

HLTRF SharesGrow Score Overview

28/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HLTRF

No analyst coverage available for this stock.

HLTRF: -2.6%/yr revenue is, +15.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet HLTRF: Debt-to-Equity (D/E) ratio 0.81 (moderate), Current ratio is 1.11 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

HLTRF: Gross margin is 42.5% (-49.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate HLTRF as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

HLTRF: Net profit margin is -22.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range2.96-4.02

Volume3K

Avg Volume (30D)133

Market Cap$100.39M

Beta (1Y)0.81

Share Statistics

EPS (TTM)-0.40

Shares Outstanding$31.53M

IPO Date2010-01-27

Employees92

CEOCraig Stuart Millian

Financial Highlights & Ratios

Revenue (TTM)$56.47M

Gross Profit$24.01M

EBITDA$18.02M

Net Income$-12.65M

Operating Income$-4.18M

Total Cash$11.7M

Total Debt$49.73M

Net Debt$38.03M

Total Assets$137.28M

Price / Earnings (P/E)-8

Price / Sales (P/S)1.78

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryCA

ExchangeOther OTC

CurrencyUSD

ISINCA40390B1094

Price Chart

HLTRF

HLS Therapeutics Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

2.96 52WK RANGE 4.02

People Also View

Knight Therapeutics Inc.

Cipher Pharmaceuticals Inc.

Cannara Biotech Inc.

RAMM Pharma Corp.

Crescita Therapeutics Inc.

Aion Therapeutic Inc.

Bionoid Pharma Inc.

City View Green Holdings Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message